BR112018074608A2 - composto, composição farmacêutica e uso de um composto - Google Patents
composto, composição farmacêutica e uso de um compostoInfo
- Publication number
- BR112018074608A2 BR112018074608A2 BR112018074608-8A BR112018074608A BR112018074608A2 BR 112018074608 A2 BR112018074608 A2 BR 112018074608A2 BR 112018074608 A BR112018074608 A BR 112018074608A BR 112018074608 A2 BR112018074608 A2 BR 112018074608A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- therapy
- relates
- present
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 abstract 1
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 abstract 1
- 102000052502 human ELANE Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
a presente invenção refere-se a derivados da imidazolona que apresentam propriedades inibitórias da elastase neutrofílica humana, e seu uso na terapia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16172196.4 | 2016-05-31 | ||
EP16172196 | 2016-05-31 | ||
PCT/EP2017/062754 WO2017207430A1 (en) | 2016-05-31 | 2017-05-26 | Imidazolone compounds as human neutrophil elastase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018074608A2 true BR112018074608A2 (pt) | 2019-03-19 |
BR112018074608B1 BR112018074608B1 (pt) | 2024-01-23 |
Family
ID=56096538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018074608-8A BR112018074608B1 (pt) | 2016-05-31 | 2017-05-26 | Composto, composição farmacêutica e uso de um composto |
Country Status (25)
Country | Link |
---|---|
US (2) | US9802919B1 (pt) |
EP (1) | EP3464273B9 (pt) |
JP (1) | JP6990663B2 (pt) |
KR (1) | KR102404031B1 (pt) |
CN (1) | CN109311850B (pt) |
AR (1) | AR108610A1 (pt) |
AU (1) | AU2017272405C1 (pt) |
BR (1) | BR112018074608B1 (pt) |
CA (1) | CA3020435A1 (pt) |
CL (1) | CL2018003417A1 (pt) |
CO (1) | CO2018012479A2 (pt) |
EA (1) | EA036456B1 (pt) |
GE (1) | GEP20207130B (pt) |
IL (1) | IL263089B (pt) |
MX (1) | MX2018014145A (pt) |
MY (1) | MY195210A (pt) |
NZ (1) | NZ747313A (pt) |
PE (1) | PE20190176A1 (pt) |
PH (1) | PH12018502242A1 (pt) |
SA (1) | SA518400429B1 (pt) |
SG (2) | SG10201912143UA (pt) |
TW (1) | TWI738786B (pt) |
UA (1) | UA123109C2 (pt) |
WO (1) | WO2017207430A1 (pt) |
ZA (1) | ZA201806743B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
JP2022534426A (ja) | 2019-05-31 | 2022-07-29 | イケナ オンコロジー, インコーポレイテッド | Tead阻害剤およびその使用 |
EP4031138A1 (en) | 2019-09-17 | 2022-07-27 | Mereo Biopharma 4 Limited | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
MX2022012942A (es) | 2020-04-16 | 2023-01-11 | Mereo Biopharma 4 Ltd | Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina. |
IL312002A (en) | 2021-10-20 | 2024-06-01 | Mereo Biopharma 4 Ltd | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
WO2023115043A1 (en) * | 2021-12-16 | 2023-06-22 | Orixa Therapeutics Llc | Small molecule inhibitors of pr3 and hne and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
EP1435353A4 (en) * | 2001-10-03 | 2006-01-04 | Nippon Soda Co | NEW HETEROCYCLIC COMPOUND AND ANTI-INFLAMMATORY AGENT |
GB0605469D0 (en) * | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
DE102009043260A1 (de) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
KR20120099639A (ko) * | 2009-10-02 | 2012-09-11 | 아스트라제네카 아베 | 호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물 |
GB201004178D0 (en) | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
GB201004179D0 (en) | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
JP2013177318A (ja) * | 2010-06-30 | 2013-09-09 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロピリミジノン誘導体およびその医薬用途 |
BR112015000507A2 (pt) * | 2012-07-12 | 2017-06-27 | Chiesi Farm Spa | inibição de enzimas |
NZ709153A (en) | 2012-12-18 | 2019-01-25 | Chiesi Farm Spa | Pyrimidinone derivatives having human neutrophil elastase inhibitory activity |
JP5799117B2 (ja) * | 2013-02-05 | 2015-10-21 | 大日本住友製薬株式会社 | ウラシル誘導体からなる医薬 |
RU2016123379A (ru) | 2013-12-16 | 2017-12-19 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Тетрагидротриазолопиримидиновые соединения в качестве ингибиторов нейтрофильной эластазы человека |
US9409870B2 (en) * | 2014-12-15 | 2016-08-09 | Chiesi Farmaceutici S.P.A. | Compounds |
-
2017
- 2017-05-26 SG SG10201912143UA patent/SG10201912143UA/en unknown
- 2017-05-26 AR ARP170101444A patent/AR108610A1/es unknown
- 2017-05-26 KR KR1020187033435A patent/KR102404031B1/ko active IP Right Grant
- 2017-05-26 CN CN201780031575.1A patent/CN109311850B/zh active Active
- 2017-05-26 MX MX2018014145A patent/MX2018014145A/es unknown
- 2017-05-26 EA EA201892714A patent/EA036456B1/ru unknown
- 2017-05-26 JP JP2018555572A patent/JP6990663B2/ja active Active
- 2017-05-26 SG SG11201809671PA patent/SG11201809671PA/en unknown
- 2017-05-26 US US15/606,313 patent/US9802919B1/en active Active
- 2017-05-26 NZ NZ747313A patent/NZ747313A/en unknown
- 2017-05-26 UA UAA201810656A patent/UA123109C2/uk unknown
- 2017-05-26 CA CA3020435A patent/CA3020435A1/en active Pending
- 2017-05-26 TW TW106117595A patent/TWI738786B/zh active
- 2017-05-26 EP EP17728091.4A patent/EP3464273B9/en active Active
- 2017-05-26 PE PE2018002811A patent/PE20190176A1/es unknown
- 2017-05-26 AU AU2017272405A patent/AU2017272405C1/en active Active
- 2017-05-26 BR BR112018074608-8A patent/BR112018074608B1/pt active IP Right Grant
- 2017-05-26 WO PCT/EP2017/062754 patent/WO2017207430A1/en unknown
- 2017-05-26 GE GEAP201714924A patent/GEP20207130B/en unknown
- 2017-05-26 MY MYPI2018001793A patent/MY195210A/en unknown
- 2017-09-22 US US15/712,366 patent/US10023558B2/en active Active
-
2018
- 2018-10-10 ZA ZA2018/06743A patent/ZA201806743B/en unknown
- 2018-10-19 PH PH12018502242A patent/PH12018502242A1/en unknown
- 2018-11-13 SA SA518400429A patent/SA518400429B1/ar unknown
- 2018-11-18 IL IL263089A patent/IL263089B/en unknown
- 2018-11-21 CO CONC2018/0012479A patent/CO2018012479A2/es unknown
- 2018-11-30 CL CL2018003417A patent/CL2018003417A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018074608A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BR112015014438A2 (pt) | composto, composição farmacêutica e uso de um composto | |
CO2017011851A2 (es) | Compuestos novedosos | |
BR112018012707A2 (pt) | inibidores da interação de menin-mll | |
CO2017004471A2 (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
BR112016018555A8 (pt) | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 | |
CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
BR112015022861A8 (pt) | inibidores de bromodomínio | |
BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
UY35747A (es) | Derivados sustituidos de fenilalanina | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
BR112015001096A2 (pt) | derivados de di e tri-heteroaril como inibidores de agregação de proteína | |
CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
UY35745A (es) | Derivados sustituidos de fenilalanina | |
CL2017002803A1 (es) | Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas | |
ECSP16096831A (es) | Derivados de naftiridinadiona | |
CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
BR112017012608A2 (pt) | composto, composição farmacêutica e uso de um composto | |
CL2018002368A1 (es) | Formulaciones de oritavancina | |
CL2017002449A1 (es) | Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas | |
BR112017020180A2 (pt) | derivados de aminohidrotiazina fundida em tetrahidrofurano que são úteis no tratamento da doença de alzheimer | |
BR112017024126B8 (pt) | Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos | |
BR112017012007A2 (pt) | compostos orgânicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2017, OBSERVADAS AS CONDICOES LEGAIS |